Alaunos Therapeutics Inc. (TCRT)

Alaunos Therapeutics (NASDAQ: TCRT ) stock is up on Monday despite a lack of news from the clinical-stage oncology-focused cell therapy company. There are no new press releases or filings with the Sec...

Alaunos Therapeutics (NASDAQ: TCRT ) stock is heading higher on Tuesday following the release of the clinical-stage oncology-focused cell therapy company's Q3 earnings report. The Alaunos Therapeutics...

Due to a lack of funding needs, Alaunos (TCRT) decides to end its only clinical study. The company will instead focus on its hunTR TCR discovery platform and explore broad strategic alternatives.

Here is how Alaunos (TCRT) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.

Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. DYN, SLN, TCRT, ASRT and ACER may prove to be good additions to one's portfolio.

Ziopharm (TCRT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ...

First-in-human data from two patients using TCR-T cell therapy produced, at best, one partial response. While not targeting solid tumors, approved CAR-T cell therapies do demonstrate high complete res...

VIRC, TCRT, AINC, CWEN and WHF have been added to the Zacks Rank #1 (Strong Buy) List on November 18, 2022.

Alaunos Therapeutics, Inc. (NASDAQ:TCRT ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Alex Lobo - Stern Investor Relations Kevin Boyle Senior - Chief Executive O...

Hot penny stocks to add to your watch list this week. Is it time to buy?